Symptomtext
extra dose of ACTHIB was administered to a patient with no reported adverse event; Initial information received on 01-Sep-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 6 months old male patient to whom extra dose of acthib was administered with no reported adverse event while receiving vaccine HIB (PRP/T) VACCINE [ACT-HIB]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 01-Sep-2022, the patient received 0.5 mL dose of suspect HIB (PRP/T) VACCINE (formulation and strength not reported; lot U7260AA, expiry date: 30-Mar-2023) via intramuscular route in the left vastus lateralis for prophylactic immunization. On 01-Sep-2022, (latency: same day) the patient had extra dose of acthib was administered to a patient with no reported adverse event (extra dose administered) following the administration of HIB (PRP/T) VACCINE. It was reported, "An extra dose of ACTHIB was administered to a 6 month old male patient. This was ACTHIB dose number four in the series. The patient received their third dose of ACTHIB on 11Aug2022". Action taken was not applicable. At time of reporting, the outcome was Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.